Introduction
In general, lowering low-density lipoprotein (LDL) cholesterol levels or increasing high-density (HDL) cholesterol levels in plasma reduces the risks of corona ry heart disease and atherosclerosis. Based on the preclinical findings that NK-104 is a highly potent inhibi tor of HMG-CoA reductase, the rate limiting enzyme in cholesterol biosynthesis,1) this agent is promising as a therapeutic drug for hyperlipidemia in humans. The 14C-labeled NK-104 was absorbed well from the intesti nal tract after oral administration to rats and distributed in the liver at a high concentrations in the unchanged form. The drug distributed in the liver was mainly ex creted in the bile and reabsorbed by entero-hepatic circulation.2) In addition, the Cmax of NK-104 reached a steady state within the 4th dosing after repeated ad ministration in rats.3) These pharmacokinetic profiles suggest that NK-104 has selectivity for the liver and long acting HMG-CoA reductase inhibitory effects.
The toxicity and/or the efficacy of a drug in animals or humans are often related to its pharmacokinetics and metabolism. In particular, considerable attention has been paid to interspecies variation in the pharmacokinet ics and metabolism. This study examined basic phar macokinetics of NK-104 in four animal species, rats, rab bits, monkeys, and dogs, and in humans. We also carried out a series of metabolic studies involving bile in rats, feces in dogs, and plasma and urine in dogs and humans.
Materials and Methods
Materials
The NK-104 (monocalcium bis [(3R,5S,6E)-7-[2 cyclopropyl-4 (4-fluorophenyl) -3-quinolyl]3.5-dihy droxy-6-heptenoate]) and its metabolites which were determined by NMR and LC-MS spectrometry in the bile of animals after an intravenous infusion4) (NK-104 lactone, M-2, M-3, M-4, M-5, M-6, M-7, M-8, M-9, M-10 and M-11) were synthesized by Nissan Chemical Industries, Ltd. (Funabashi, Japan). The structures of NK-104 and its metabolites are shown in Fig. 1 . All other solvents and chemicals were obtained commercial ly, and were of HPLC grade or extra pure grade.
Animals
Wistar strain (specific pathogen-free) male rats, weighing about 200 g, JW strain male rabbits, weighing about 2.5 kg, HRA-male beagle dogs, weighing about 10 kg (Japan Laboratory Animal Inc. Tokyo, Japan) and male cynomolgus monkeys, weighing about 4 kg (Philippines born, Japan SLC. Inc. Shizuoka, Japan) were used. The rats and rabbits were acclimatized for at least 4 days, and all animals were kept in a controlled care room at the temperature of 23±2°C and a relative humidity of 60±10%. All animals were maintained on laboratory chow diets and were fasted overnight prior to the drug administration, but had free access to water. Three or four animals were assigned to each test group.
Pharmacokinetic
Study in Animals 1) Intravenous Administration Study The dosage form of NK-104 was prepared as a solu tion in physiological saline at a range of 0.1-1 mg/ml for intravenous administration. The rabbits and dogs were intravenously given 0.1 mg/kg, the monkeys and rats were intravenously given 0.3 and 1 mg/kg of NK 104, respectively. The dose levels were quoted from the mini mum dose of oral administration and our previous study.2 The intravenous bolus injection was made in the front leg vein of dogs, the femoral vein of monkeys, the ear vein of rabbits and the tail vein of rats. Blood sam ples were withdrawn from the jugular vein of rats, from the ear vein of rabbits, from the front leg vein of dogs and from the femoral vein in monkeys at the indicated times. Plasma was separated after centrifugation of blood sample. The plasma samples were stored at -20°C until analyzed .
2) Oral Administration Study NK-104 was prepared as a suspension in 0.5% sodi um carboxymethyl cellulose solution at a range of 0.1-5 mg/ml for oral administration. The rabbits and dogs were given NK 104 in single oral administration of 0.1, 0.3 or 1 mg/kg. The rats and monkeys were given NK 104 at 0.3, 1 or 3 mg/kg. The collection of blood sam ples was carried out in the same manner as for the in travenous administration.
3) Excretion of NK-104 in Urine and Feces Rats were housed individually in glass metabolic cages (Metabolica®; Sugiyamagen Iriki, Tokyo, Japan) after intravenous or oral administration of NK 104. The other animals were maintained individually in stainless steel metabolic cages. Urine and feces were collected separately every 24 h up to 72 or 96 h after the adminis tration. Each urinary sample was diluted with water. Each fecal sample was homogenized with water. Ali quots (0.5 ml or 0.5 g) of urine and fecal homogenates were stored at -20°C until analyzed. 4. Biliary Metabolites in Rats Rats were surgically prepared with common bile duct cannulae under ether anesthesia. After awakening, NK 104 was orally administered at a dose of 1 mg/kg and each animal was housed individually in a Bollman's cage (Natsume Seisakusyo, Tokyo, Japan). The bile was con tinuously collected for 24 h in the dark to prevent the degradation of biliary metabolites. The biliary samples were stored at -20°C until analysis.
Plasma, Urinary and Fecal Metabolites in Dogs
The plasma, urinary and fecal metabolites were inves tigated in dogs after intravenous administration of NK 104 at a dose of 0.1 mg/kg and oral administration at 1 mg/kg and 10 mg/kg. The administration procedure and the collection of biological samples were carried out as described above. Aliquots of plasma, urinary and fe cal samples were stored at -20°C until analysis.
6. Repeated Administration of NK-104 in Humans Five healthy male volunteers (age, 22-24 years) received repeated oral administrations of NK-104 at a dose of 2 mg as a tablet once a day for five days. In this study, not only the plasma concentration of NK-104 but also the plasma and urinary metabolites of NK-104 were investigated. The protocol was approved by the Niza Shiki Central Hospital Ethical Committee, and the sub jects had given their informed consent. Blood samples were taken via an antecubital vein at various times up to 48 h after the final administration for the parent drug and its lactone assays, and at 1.5, 6 and 24 h on day 1 and day 5 for the metabolites assay. Urine samples were collected every 24 h after daily administration. Aliquots of plasma and urinary samples were stored at -20°C un til analysis.
Enzymatic Hydrolysis
To confirm the presence of conjugates of NK-104 and its metabolites, the urinary, fecal and biliary samples were treated with enzymatic hydrolysis. The incuba tions of the urinary, fecal and biliary samples were car ried out with fl-glucuronidase/arylsulfatase (5000 fishman units and 80 units) at 37°C. The amounts of con jugates were calculated by subtracting the concentra tion of enzyme-untreated samples.
Analytical Methods 1) Preparation of Standard Solution
Quantitative analysis of NK-104 and NK-104 lactone in the biological samples was performed by a column switching-HPLC method described in our previous report.5> The other NK-104 metabolites, M-2 (NK-104 dehydrolactone), M-3 (5-keto NK-104), M-4 (3-de hydroxy NK-104), M-5 (pentadienoic acid derivative), M-6 (pentenoic acid derivative), M-7 (hydroxypen tenoic acid derivative), M 8 (propenoic acid derivative), M-9 (propanoic acid derivative), M-10 (taurine con jugate of pentadienoic acid derivative) and M-11 (tau rine conjugate of pentenoic acid derivative) were meas ured by the five methods as described in Table I . The stock solutions of NK-104, M-3, M-4, M-5 , M-6, M-7, M-8, M-9, M-10 and M-11 were prepared in water , whereas those of M-2 and NK-104 lactone were pre pared in methyl tert butyl ether (MTBE). The stock so lutions of NK-104 and its metabolites were diluted with water or MTBE to appropriate concentrations for stan dard preparation. These solutions were stored in the dark at 4°C.
2) Sample Preparation In Methods 1, 3, 4 and 5, the internal standards were added to biological samples in a colored tube, and then 1 M potassium dihydrogenphosphate was added. These mixtures were extracted with 6 ml of MTBE and subse quently centrifuged at approximately 700 g. In the Method 1, the organic layer was transferred to another colored tube and then diazomethane-ether solution (0.5 ml) was added. After 0.5 h, excessive diazomethane was degraded by the addition of 1 M potassium di hydrogenphosphate (2 ml), and the organic layer was evaporated to dryness under a gentle stream of nitrogen at 40°C. In the Methods 3, 4 and 5, the organic layer was also transferred to another colored tube and was evapo rated to dryness. In the Method 2, the unextractable fractions of biological samples were further extracted by chloroform after addition of 50 mM tetrabutylammoni um hydrogen sulfate (TBAS). After the extraction, the organic layer was transferred to another colored tube and was evaporated to dryness. Each residue was dis solved in 150 ul of the mobile phase, and an aliquot of 80 ul was injected into an HPLC system.
3) Column Switching-HPLC The HPLC-chromatographic system (LC-6A or 1OA series, Shimadzu, Kyoto, Japan) consisted of two pumps, an automatic sample injector and a high-pres sure six-port valve. A UV detector linked to a data sys tem was used for data acquisition and storage. The chro matographic signals were monitored at 250 nm for the quantification of NK-104 and its metabolites. The column switching according to valve operation was car ried out automatically by the SCL-6A or a 10A con troller programed valve rotation time. Two columns were used for the pre-separation and analytical separa tion, respectively. The injected samples were first sepa rated on the pre-column, and the flow path was switched to the analytical column, transferring analytes from the pre-column to the analytical column. The chromato graphic conditions of column switching are shown in Table I .
Calculations
The pharmacokinetic parameters were calculated from the individual plasma concentration-time curve of NK-104 and its metabolites in each animal species and humans. The plasma concentration curves of NK-104 after intravenous administration could be adequately de scribed by an exponential equation, Cp=Pe-nt+Ae-c,,+ Be-#'. The observed data were fitted in the triexponen tial equation using a nonlinear least-squares curve fitting program.6) The elimination half-life (t1/2) value was esti mated by using the least square method of actual data. The area under the plasma concentration-time curve (AUC) value was obtained by the trapezoidal rule. The plasma clearance (Clp) was estimated by the relation ship of dose/AUC. After oral administration, the maxi mum concentration (Cmax) of analyte was read directly from the concentration-time data. The bioavailability (BA) was calculated from the dose-normalized AUC ob tained from oral and intravenous administrations. The excretion of NK-104 and its metabolites in urine, feces and bile was corrected to the % of dose. Each value represents the mean--!: S.E. of 3-6 animals or humans. 
Results

Pharmacokinetics
Studies 1) Intravenous Administration in Animals (Fig. 2 , Table II ) The plasma concentration of NK-104 after in travenous administration of 1 mg/kg to rats, 0.1 mg/kg to rabbits and dogs, and 0.3 mg/kg to monkeys showed a triexponential elimination with half-life values for the terminal phase (t1/2) of 3.97, 5.06, 4.60 and 5.31 h, re spectively. The plasma clearance (Clp) values in rats, rabbits, dogs and monkeys were 11.6, 1.0, 5.8 and 10.3 ml/min/kg, and the distribution volume of steady-state (Vss) values were 1.34, 0.38, 0.97 and 1.53 L/kg, re spectively. The ratios of blood to plasma concentration (RBP) up to 2 h after administration showed an almost constant value of approximately 0.6 in all species, in dicating that the distribution of NK-104 into erythro cytes was small. Although the NK-104 lactone in plas ma after administration was not found in rats, this metabolite was detected in the other three species. The species difference in pharmacokinetic parameters of NK-104 lactone was also observed not only in the Tmax values (0.03-2.00 h) but also Cma,, values (7, 12 and 118 ng/ml in rabbits an dogs at 0.1 mg/kg and monkeys at 0.3 mg/kg, respectively). 2) Oral Administration in Animals (Fig. 3 , Table  III ) After oral administration at a dose of 0.3, 1 and 3 mg/ kg to rats, NK-104 was rapidly absorbed and reached maximum levels within lh independent of the dosage. The Cmax values increased more than dose-proportional ly in the dose range. The increase in AUC was largely dose-proportional up to a dose of 1 mg/kg, but dose proportional from 1 to 3 mg/kg. The plasma concentra tions of NK-104 exhibited a biexponential decrease , and the t1/2 in the last phase was about 7 h at a dose of 1 mg/ kg. The BA in rats was 80% at a dose of 1 mg/kg. In ad dition, the NK-104 lactone in the rat plasma was not de tected.
In rabbits, the Cm. and AUC values of NK-104 in creased linearly in the tested dose range of 0.1 to 1 mg/ kg. Although the plasma concentrations of NK-104 were declined moderately up to 10 h after administra tion, thereafter its elimination t1/2 was about 4 h at a dose of 1 mg/kg. The BA in rabbits was 97%. The Cmax of NK-104 lactone as a metabolite after administration at 1 mg/kg was 21.1 ng/ml, only 1/56 of the Cm. of NK-104.
In dogs, the Cm,-, and AUC values of the parent drug increased dose-proportionally as they did in rabbits. The plasma concentrations of NK-104 exhibited an exponen tial decrease, and its t1/2 was about 4 h in the 1 mg/kg ad ministration. The BA in dogs was 88% at a dose of 1 mg/kg. The Cm. of NK-104 lactone after administra tion at 1 mg/kg was 117 ng/ml, about 1/6 compared with the Cmax of NK-104.
In monkeys, the Cmax and AUC values of the parent drug also increased linearly in the dose range of 0.3 to 3 mg/kg, and the t1/2 values were similar to those of the rabbits and dogs. However, the BA in monkeys was 18Y6, lower than those of the other animal species. The Cmax of NK-104 lactone after administration at 1 mg/kg was very low (9.4 ng/ml). 3) Urinary and Fecal Excretion in Animals  Fig. 4 shows the excretion ratio of NK-104 in the urine and feces up to 72 or 96 h after intravenous ad ministration at a dose of 0.1-1.0 mg/kg, and after oral administration at a dose of 1 mg/kg to the four animal species. The excretion was nearly complete in the first 24 h after administration (data not shown). After oral administration, the drug was excreted mainly into feces in rats and dogs as the unchanged form, accounting for 61.6 and 46.2% of the dose, respectively. The urinary ex cretions were practically negligible in both species, in dicating less than 1 YO of the dose. The NK-104 was ex creted mainly into urine in rabbits (35.7% of dose), while the fecal excretion was only 13.0% of dose. The excretion of unchanged NK-104 in monkeys was slight, being 0.1 and 5.2% of the dose into urine and feces, re spectively.
The NK-104 lactone and the glucuronic acid con jugates of NK 104 and NK 104 lactone were excreted at less than 5% of the dose in all species after oral ad ministration. In addition, no essential changes were not ed in the excretion ratio at any dose after oral administra tion of NK-104 (data not shown). After intravenous ad ministration, the urinary and fecal excretions of NK 104, NK-104 lactone and the glucuronic acid conjugates were similar to those in the oral dose study in all species.
Biliary Metabolites in Rats (Table IV) In bile, the unchanged NK-104 accounted for 32.3% of the dose. The metabolites of NK-104, M-3 (5-keto NK-104), NK-104 lactone, M-11 (taurine conjugate of pentenoic acid derivative), M-10 (taurine conjugate of pentadienoic acid derivative) and M-6 (pentenoic acid derivative) accounted for 7.1, 5.6, 3.1, 2.0 and 1.5% of the dose, respectively. M-7 (hydroxypentenoic acid derivative) and M-8 (propenoic acid derivative) ac counted for less than 0.3% of the dose. After the en zymatic hydrolysis of bile, M-6 accounted for 11.2% of the dose. The other glucuronic acid conjugate metabo lites accounted for less than 1.0%. No other metabolites were determined in rat bile. The total recovery of NK 104 and its metabolites was about 65% of the dose up to 24 h. Plasma Metabolites in Dogs (Fig. 5 , Table V) After intravenous administration, the unchanged NK 104 was mainly found in the plasma and showed a triex ponential elimination. The AUC values of NK-104, NK 104 lactone, M-5 (pentadienoic acid derivative) and M 3 were 0.398, 0.042, 0.025 and 0.002 ug h/ml, respec tively. After oral administration at a dose of 1 mg/kg, the parent drug appeared rapidly in plasma, and the Cmax was 526 ng/ml. The AUC values of NK-104, NK-104 lactone, M-5 and M-3 were 1.59, 0.44, 0.17 and 0.02 ug h/ml, respectively. At a dose of 10 mg/kg, the AUC of NK-104, lactone and M-5 were 35.5, 14.5 and 7.6 ug h/ ml, respectively. Moreover, the t1/2 of M-5 was 13.8 h. The concentrations of M-3, M-4, M-6 and M-7 were also detected as minor metabolites. Although M-8 was also a minor metabolite, the t1/2 was 28.4 h. No other metabolites were found in dog plasma at any dosing. (Table VI) The unchanged NK-104 was excreted mainly in feces after intravenous and oral administrations to dogs. After intravenous administration at a dose of 0.1 mg/kg, the unchanged NK-104 in feces was 31.1% of the dose. The excretions of M-5 and NK-104 lactone were 2.2 and 0.3% of the dose, respectively. The total recovery of NK-104 and metabolites reached about 34% of the dose. The excretions of NK-104 after oral administra tion at 1 mg/kg and 10 mg/kg were 49.9 and 38.7%; those of NK-104 lactone were 2.6 and 2.3%, and those of M-5 were 1.7 and 1.8% of the dose. M-2 (NK-104 de hydrolactone), M-3, M-4, M-6, M-7 and M-8 were slightly detected in feces; the excretion ratios were less than 0.3% of the dose. No other metabolites were detect ed in the feces. The total recovery of NK-104 and its metabolites at 1 mg/kg and 10 mg/kg was about 55 and 44% of the dose, respectively. The urinary excretion of NK-104 at both doses was less than 0.2% of the dose, and the excretions of metabolites were negligible. After enzymatic hydrolysis, no marked difference was noted in the relative amounts of NK-104 and its metabolites in the urine and feces (data not shown).
Urinary and Fecal Metabolites in Dogs
Repeated
Administration of NK-104 to Humans (Fig. 6 , Table VII) After repeated oral administration of NK-104 to hu mans, the unchanged NK-104 appeared rapidly in the plasma. The Cmax value of NK-104 was 36.3 ng/ml on day 1, and slightly increased to the Cmax of 41.4 ng/ml on day 5. Subsequently, the concentration of NK-104 declined with the t1/2 of 13.1 h. NK-104 lactone was found in plasma as a major metabolite of NK-104. The Cmax value of NK-104 lactone was 19.5 ng/ml on day 1, and the Cmax of 21.5 ng/ml was observed on day 5. Sub sequently, the concentration of NK-104 lactone decreased with the t1/2 of 12 h on day 5. Due to the repeated administration, the AUC values of NK-104 and NK-104 lactone on day 5 were increased by about 20% compared to day 1. M-9 was slightly detected at 6 and 24 h on day 5, whereas the level of M-9 was negligible. No other metabolites were detected in human plasma during the repeated administration (data not shown). Moreover, no remarkable difference was observed in the other pharmacokinetic parameters during the repeated oral administration.
Urinary Metabolites in Humans (Table VIII) The urinary excretions of NK-104 and NK-104 lac tone were 0.7% and 1.7% of the dose, respectively. The excretion of M-2 was slight in urine (0.1Y0 of the dose). No other metabolites were detected in human urine dur Cable VII Pharmacokinetic paramerters of NK-104 and lactone after repeated oral administration of NK-104 at a dose of 2 mg once a day for five days to subjects ing the repeated administration. After enzymatic hydrol ysis, the total excretion ratio of the glucuronic acid con jugate of NK-104 and NK-104 lactone was about 4°/ of the dose.
Discussion
In the present study, the interspecies variation on the pharmacokinetics and metabolism of NK-104 was inves tigated after intravenous and/or oral administration to animals and humans. Human data were quoted from a phase-one clinical study').
The plasma concentration of unchanged NK-104 and its lactone form after an intravenous administration to rats, rabbits, dogs and monkeys decreased triexponen tially, and the terminal half-life 41/2) values were about 5 h in all species. The distribution volumes of steady state (Vss) and the plasma clearance (Clp) values showed a large difference. Therefore, marked species differences were observed in the distribution into sys temic tissues, and in the systemic clearance.
After oral administration, NK-104 was well absorbed and the t1/2 of the terminal phase in each species was similar to that after intravenous administration. Moreover, high bioavailability (BA) was observed in all species except monkeys. The relationship between oral dosage and AUC was apparent linear in the relatively high dose range in all species; however, the correlation lines were not extrapolated through the origin. Moreover, the improvement of BA was observed as the increase of dose in all species except monkeys. These results indicated that the saturated metabolism might affect the plasma concentration of minimum dose after oral administration. On the other hand, the results previ ously reported for humans,7) are presented in Fig. 7 for comparison with these animal data. The correlation line for humans was well extrapolated through the origin, even at the low dosage. The correlation line for humans was located between those of dogs and rats. In addition, NK-104 lactone was found in the plasma of dogs and hu mans as the major metabolite of this drug, suggesting that the pharmacokinetics of NK-104 in humans resem ble those in dogs. We expected that the monkeys would show the pharmacokinetic model most similar to that of humans. In the monkeys, however, that NK-104 may be most markedly metabolized compared with the other animal models. In particular, the pharmacokinetic parameters of the AUC and BA in monkeys showed sig nificantly lower values than in other species.
It has been reported that the BA of other HMG-CoA reductase inhibitors (statins), i.e, pravastatin, fluvasta tin, and cerivastatin, was 37, 41 and 67%, respec tively, [8] [9] [10] in dogs. The BA of fluvastatin and cerivasta tin in rats was 46% and 26%, respectively. 10,11) However, the BA of NK 104 at 1 mg/kg was considera bly high in dogs and rats of the present study (80% or more) compared with other statins. We suspect that NK-104 was excreted mainly into bile as the unchanged form and was reabsorbed by the entero-hepatic circula tion, suggesting that the apparent BA of NK-104 in animals was high.
The lactone form of NK-104 was not detected in plas ma after intravenous and oral administrations of NK 104 to rats; however, this metabolite was determined although at significantly lower levels than the parent drug in plasma of rabbits, dogs, and monkeys. In hu mans, the Cmax of NK 104 lactone showed a level of ap proximately half in comparison with the parent drug, in dicating that lactonization was the major metabolic path way. Interestingly, the lactonization of NK-104 is a de hydrated reaction unparticipating with cytochrome P 450 enzymes. Since the HMG-CoA reductase inhibitors, lovastatin and simvastatin are lactone prodrugs that become active inhibitors upon hydrolytic conversion,'2) NK-104 lactone would be reversibly converted to NK 104 in humans.
The total excretion ratio of NK-104 and its lactone reached more than 40% of the dose independently of on the administration route in all animal species tested here except monkeys. In addition, the main excretion path way of NK-104 in rabbits was the renal route. It has been also reported that several other statins are mainly excreted via bile in most animal species.u,13) However, the urinary excretion of 14C-fluvastatin in rabbits reached about 32% of the total radioactivity. 14) These results suggest that the renal route may be a major ex cretion pathway of statins in rabbits. In rats and dogs, the unchanged NK-104 was excreted mainly in feces. The urinary excretion rates of NK-104 and NK-104 lac tone in both species were low (less than 2 % of the dose), indicating that the urinary excretion pattern in both rats and dogs resembles that in humans, suggesting that NK-104 may be excreted in feces via biliary excretion in humans.
We have previously reported that the biliary excretion of 14C-NK-104 was 75% up to 48 h after oral administra tion in rats and that most of this drug was subjected to entero-hepatic circulation.2) The remarkable inhibitory effect of sterol synthesis in rat was observed until 6hr after administration of NK-104 and the concentration of unchanged NK-104 in liver was about 70 fold higher than that in plasma.') These results suggested that the entero-hepatic circulation of NK-104 related to the dura tion of drug effect. The metabolic pattern in rat bile was further examined in the present study. The unchanged NK 104 accounted for 32% of the dose in bile until 24 h after administration. On the other hand, the metabolites of NK-104 were also excreted in bile. Moreover, NK 104 and its metabolites were detected in dog feces, in dicating that elimination pathway of this drug and metabolites were hepatobiliary excretion. It was recent ly reported that the carrier-mediated transporter contrib utes to the hepatobiliary excretion of many drugs.15) In particular, a primary active transport mechanism has been shown to be responsible for the biliary excretion of organic anions including glucuronic acid conjugates. 16.17) Therefore, some metabolites of NK 104 are probably eliminated by the hepatobiliary trans port mechanism because these metabolites are also or ganic anions as well as NK-104.
We also investigated the metabolic patterns of NK 104 in plasma of dogs; these patterns resemble the NK 104 pharmacokinetics in humans. No marked difference was observed in the ratios of metabolites between in travenous and oral administrations to dogs. The ratios occupied by the unchanged NK-104 in plasma after ad ministration to dogs were much higher than those of ev ery metabolite. NK-104 lactone and M-5 were detected as minor metabolites. In addition, M-5 and M-8, which were formed at the latter stage of the metabolic path way, were maintained up to 8 h, and their elimination was also considerably slow at a dose of 10 mg/kg. These results suggest that although NK-104 was scarcely metabolized in dogs, the elimination rates of minor metabolites (M-5 and M-8) were lower than that of NK-104.
The M-5 and M-8 metabolized from NK-104 are products of /t-oxidation of the heptenoic side chain, and they possess a mono-carboxylate moiety. It has been reported that the mono-carboxylate transport system plays important roles in the transport of short-chain mono-carboxylic acids at the plasma membrane of the heart and skeletal muscle. 18, 19) Since the retention of M 6 and M-8,,6-oxidation products of NK-104, has been previously observed in these tissues of rats,2) we sug gest that M-5 and M-8 in plasma of dogs also may be transported across the plasma membrane via the mono carboxylate transporter in the heart and skeletal muscle.
In the present study, we also determined NK-104 and its metabolites in plasma and urine after a repeated oral administration to healthy human volunteers at 2 mg/sub ject once a day for 5 days. The variations of inter AUC and inter-Cm of NK-104 in humans were about 3 folds. However, no marked difference was noted between the humans and animals in the variation of inter-plasma con centration. After this oral administration to humans, the unchanged NK-104 and its lactone were mainly ob served in plasma. On the other hand, a slight amount of metabolites were detected. These findings suggest that NK-104 is hardly metabolized in the human liver more than in each animal species. The t1/2 (13.1 h) of the ter minal phase in humans was thus longer than those in the animal species studied (4-7 h) and these results indicat ed that NK-104 was subjected to entero-hepatic circula tion in human.
Compared with the biotransformation of other statins, lovastatin was extensively metabolized by two major pathways, namely the cytochrome P-450-mediated oxi dation of the fused-ring system and the fit-oxidation of the heptanoic acid side chain after hydrolysis of the lac tone ring.20) Fluvastatin was completely metabolized by the hydroxylation of the indole ring, the loss of the 1 isopropyl group, /3-oxidation, lactone formation, the for mation of the threo-isomer and conjugation with glucuronic acid or sulfate.21) In contrast, pravastatin was metabolized by /3-oxidation, lactone formation, isomerization and conjugation with glutathione.13> It has been reported that cerivastatin is also susceptible to being metabolized by cytochrome P-450-mediated hydroxylation and 8-oxidation.22) A remarkable differ ence was observed in the metabolic pathway between NK-104 and other statins in the ring hydroxylation, which is the major metabolic pathway of other statins.
We therefore find that the most interesting features of NK-104 is that it is hardly metabolized via cytochrome P-450 mediated oxidation and/or ,6-oxidation in hu mans. The pharmacokinetic properties of NK-104 in hu mans are good absorption, a relatively long t1/2 and possi bly high bioavailability. We speculated that these favora ble metabolic and pharmacokinetic characteristics of this drug support efficacy in clinical studies23z4) as a hypolipidemic and antiatherosclerotic agent in humans.
